Retatrutide (5mg)

Description

Product Overview

Retatrutide is an investigational triple-agonist peptide drug designed to activate GLP-1, GIP, and glucagon receptors.
Developed by Eli Lilly & Company, it aims to deliver unmatched weight loss, metabolic improvement, and potential liver health benefits.

Chemistry & Format

• Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈

• Molecular Weight: ~4,731.33 g/mol

• Form: White lyophilized powder for reconstitution

• Storage: Refrigerated (2–8 °C)

Mechanism of Action

• Stimulates insulin secretion

• Suppresses appetite

• Increases energy expenditure via fat metabolism

• Targets three pathways at once (GLP-1, GIP, glucagon receptors)

Efficacy Highlights

• Weight Loss: Up to 24% of body weight in under a year in Phase 2 trials

• Other Benefits:

  • Reduced liver fat

  • Improved cholesterol

  • Lower blood pressure

  • Better blood glucose control

Dosage

Note: Retatrutide is still in clinical trials. The following reflects investigational protocols — not an approved prescribing guideline.

• Starting Dose: Often begins at 2 mg weekly, increasing over several weeks

• Titration: Dose adjusted gradually to minimize gastrointestinal side effects

• Highest Trial Dose: 12 mg weekly in Phase 2 studies

• Administration: Subcutaneous injection (abdomen, thigh, or upper arm)

• Reconstitution: Lyophilized powder is mixed with sterile water before use

Safety & Side Effects

• Common: Nausea, diarrhea, constipation

• Less common: Vomiting, decreased appetite

• Early concerns: Possible effects on bone density and kidney function

• Long-term safety still under investigation

FAQs

Q: How does it compare to Ozempic or Mounjaro?
A: In early studies, Retatrutide showed greater average weight loss (up to ~24%) than current GLP-1/GIP drugs.

Q: How is it stored?
A: Retatrutide is kept refrigerated and protected from light until reconstitution.

Q: Can it treat diabetes?
A: While its primary focus is weight management, it also improves blood sugar control, making it a potential future therapy for type 2 diabetes.